CLOSE X

AARTI PHARMALABS LTD.

NSE : AARTIPHARMBSE : 543748ISIN CODE : INE0LRU01027Industry : Pharmaceuticals & DrugsHouse : Private
BSE869.00-4 (-0.46 %)
PREV CLOSE ( ) 873.00
OPEN PRICE ( ) 873.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 866.20 (5)
VOLUME 8364
TODAY'S LOW / HIGH ( )863.50 881.00
52 WK LOW / HIGH ( )495.6 882.95
NSE866.40-7.5 (-0.86 %)
PREV CLOSE( ) 873.90
OPEN PRICE ( ) 875.80
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 866.40 (50)
VOLUME 244110
TODAY'S LOW / HIGH( ) 862.30 881.65
52 WK LOW / HIGH ( )497.05 883.8
GO
(Rs.in Million)
Particulars
Mar 2025
Dec 2024
Sep 2024
Jun 2024
Audited / UnAudited
UnAudited
UnAudited
UnAudited
UnAudited
Net Sales
5637.77
5377.78
4580.26
5554.93
Total Expenditure
4181.50
4091.69
3643.52
4590.33
PBIDT (Excl OI)
1456.27
1286.09
936.74
964.60
Other Income
-16.08
50.28
44.83
22.16
Operating Profit
1440.20
1336.37
981.57
986.77
Interest
65.83
99.74
55.06
48.33
Exceptional Items
NA
NA
NA
NA
PBDT
1374.37
1236.63
926.51
938.44
Depreciation
228.16
230.38
208.83
201.68
Profit Before Tax
1146.21
1006.25
717.68
736.76
Tax
262.79
266.38
171.45
182.23
Provisions and contingencies
NA
NA
NA
NA
Profit After Tax
883.42
739.87
546.23
554.53
Extraordinary Items
NA
NA
NA
NA
Prior Period Expenses
NA
NA
NA
NA
Other Adjustments
NA
NA
NA
NA
Net Profit
883.42
739.87
546.23
554.53
Minority Interest
NA
NA
NA
NA
Shares of Associates
Other related items
Misc. Expenses Written off
NA
NA
NA
NA
Consolidated Net Profit
883.41
739.88
546.22
554.54
Equity Capital
453.17
453.13
453.13
453.13
Face Value (IN RS)
5.00
5.00
5.00
5.00
Reserves
NA
NA
NA
NA
Calculated EPS
9.75
8.16
6.03
6.12
Calculated EPS (Annualised)
38.99
32.66
24.11
24.48
No of Public Share Holdings
50493424.00
50156614.00
48845423.00
48519423.00
% of Public Share Holdings
55.71
55.34
53.90
53.54
 
NA
NA
NA
NA
PBIDTM% (Excl OI)
25.83
23.91
20.45
17.36
PBIDTM%
25.55
24.85
21.43
17.76
PBDTM%
24.38
23.00
20.23
16.89
PBTM%
20.33
18.71
15.67
13.26
PATM%
15.67
13.76
11.93
9.98
 
Notes
Notes
Notes
Notes
ATTENTION INVESTORS NSDL/CDSL KYC Advisory for investors